Press Release Services and Business News from Send2Press, a unit of Neotrope, established 1983
Press Release Writing and Distribution
  Saturday, March 25, 2017 Neotrope®
Public Relations
Press Release Services and Media Relations
Send2Press® - Press Release Writing, Newswire Distribution, Press Release Optimization, Internet Marketing, Podcasting, SEO, Media Monitoring, Media Coaching, News Syndication, Book Marketing, Entertainment News, Web PR, and Media Relations since 1983   media relations
press release writing
Press Release Services and Business News from Send2Press, a unit of Neotrope, established 1983
 
NEWS WIRES:
» Ad Industry News
» Aerospace News
» Arts News
» Automobile News
» Biotech News
» Book News
» Business News
» Computer Industry News
» Construction News
» DotCom News
» eCommerce News
» Education News
» eMarketing News
» Entertainment News
» Employment News
» Energy News
» Family/Parenting News
» Fashion Industry News
» Fitness Industry News
» Food & Cooking News
» Graphics News
» Insurance News
» Interior Design News
» Internet News
» Investor News
» Manufacturing News
» Medical News
» Music News
» NonProfit News
» Peace/Ecology News
» Podcasting News
» Political News
» Real Estate News
» Religion News
» Retail News
» Security Solutions News
» Small Cap & OTC News
» Software Industry News
» Sports News
» Telecom News
» Travel Industry News
» TV & Cable News
» VoIP News
» US Newswires
» Business Profiles
» More News Channels
» Today's Headlines

Distribute your News with Send2Press® Press Release Services

 

Medical Technology and Biotech News
Recent News Stories from PRnetwire.com >> News Article

Edited by Christopher Simmons, senior news editor


EPEIUS BIOTECHNOLOGIES CORPORATION GAINS FDA ORPHAN DRUG APPROVAL FOR REXIN-G, THE WORLD'S FIRST TARGETED INJECTABLE GENE THERAPY VECTOR, FOR PANCREATIC CANCER

LOS ANGELES, Calif. - Sept. 8, 2003 (Send2Press Newswire) -- Epeius Biotechnologies Corporation ( Epeius, www.epeiusbiotech.com ) today announced that the FDA has approved REXIN-G, the world's first tumor-targeted injectable gene therapy vector, as an orphan drug for pancreatic cancer. The FDA's decision to approve REXIN-G was based on objective demonstrations of medical plausibility of REXIN-G as an effective treatment for pancreatic cancer. The major benefit to the company is market exclusivity for the REXIN-G product for all types of pancreatic cancer. This represents a highly significant milestone for Epeius Biotechnologies since its lead product, REXIN-G, is the first gene therapy product to gain FDA orphan drug designation for pancreatic cancer.

Epeius also announced that the Company has executed a screening agreement with the National Cancer Institute wherein NCI scientists will evaluate the activity of REXIN-G and other promising targeted gene therapy products at the NCI. In an interview with Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies, Dr. Hall emphasized that "Federal and State support is vital to an emerging biotech company like Epeius, to expedite the advancement of REXIN-G and other targeted genetic medicines to the clinic for the benefit of cancer patients. The screening agreement is an important first step."

ABOUT EPEIUS:
The mission of Epeius Biotechnologies is to develop and commercialize the first truly effective Targeted Delivery System (TDS) that can be injected directly into a vein to deliver genes and molecular therapeutics preferentially to cancerous tumors that have spread throughout the body (metastatic cancer), without eliciting systemic side effects or organ damage. REXIN-G is the first targeted injectable gene therapy vector that has been approved by both the U.S. FDA and the Philippine BFAD (FDA counterpart) for use in Phase I/II cancer clinical trials.

The encouraging results of the first human experience using REXIN-G as intravenous infusions for advanced pancreatic cancer will be presented at the SRI Nucleic Acid World Summit meeting in Boston on September 16, 2003 by Dr. Erlinda M. Gordon, Medical Director of Epeius.

Company Website: www.epeiusbiotech.com
Source of News: Epeius Biotechnologies Corporation

California Business Newswire / Medical Technology Newswire
> Read original news release in raw text format



> Previous News from Epeius Biotechnologies Corporation


> More Medical Technology News
> More California Business News
> Other Recent News Stories



FOR INFORMATION ABOUT THE COMPANY OR ORGANIZATION(S) MENTIONED IN THE ABOVE NEWS ITEM, PLEASE CONTACT THE COMPANY DIRECTLY. SEND2PRESS/NEOTROPE IS NOT A REPRESENTATIVE OF, AND DOES NOT OFFER FURTHER INFORMATION ABOUT, ANY COMPANY MENTIONED IN THE ABOVE NEWS ITEM.

DISCLAIMER: the above news article is believed accurate but not guaranteed, and is based on news supplied by the company or organization mentioned and/or quoted in the story. Neotrope/Send2Press makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news item are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope/Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article. Reproduction of this news article in any form requires written authorization — use of the raw text version of the news has no restrictions other than you may not post our news on a website which offers either PR or newswire services, or Internet Promotion services.. You may freely link to this article. eNewsChannels™ (www.eNewsChannels.com) is a unit of Neotrope®. Keyword marketing technology by DotComMojo™, a unit of Neotrope.  
NEWSWIRE TERMS OF USE



Add Our News Headlines to Your Website Free
Free headline feed


Journalists & Editors
Choose your news by preferred topic(s).
Privacy protected.
MORE INFO

Archived Releases

Most Recent Releases


Subscribe to RSS Feed



NOTICE: THIS PAGE IS ARCHIVAL CONTENT AND SHOULD NOT BE RELIED UPON FOR ACCURACY.
Top of Page | Home Page | E-mail This News Story
— PLEASE SUPPORT OUR NEWSWIRE ARCHIVE SPONSORS —
Press Release Services from Send2Press
Click Links Below to Learn More About Business Promotion Services:
Press Release Services from Send2Press   |   Press Release Writing Services
Search Engine Marketing Services for Your Website   |   Website Design
Small Business Media Profiles and Electronic Press Kits
Mindset Interactive, Mindset Design, Mindset Communications, Mindset Advertising, Mindset Netwire
 Copr. © 1983-2014 Neotrope® — all rights reserved. Privacy/Legal Statements 
Press Release Services and Business News from Send2Press, a unit of Neotrope, established 1983
Press Release Writing
Business Press Release Services | Compare News Distribution Plans | Agency Program | How to Order
PR Services Add-on Options | Price List | SEO+PR™ Services | Press Release Writing | Publication Lists
Client Testimonials | About Us | Contact Us | Newswire Channels |
News About Send2Press | | RSS/XML Feed

Free News Articles